CAP-CD56+CD271+ BMSCs exos-loaded PVA/SA sustained-release hydrogel attenuates chondrocyte senescence and ameliorates lumbar facet joint osteoarthritis
The CAP-CD56<sup>+</sup>CD271<sup>+</sup> BMSCs Exos-PVA/SA hydrogel sustained-release system presents a promising and effective therapeutic approach for LFJ OA.
Authors
- Quanbo Liu
- Yiguo Yan (ORCID: https://orcid.org/0000-0002-3476-109X)
- Jingbo Xue (ORCID: https://orcid.org/0000-0003-4762-9052)
- Jinghua Tan
- Yutong Li (ORCID: https://orcid.org/0000-0003-2221-7983)
- Ming Wang (ORCID: https://orcid.org/0000-0002-0384-1767)
- Cheng Wang (ORCID: https://orcid.org/0000-0002-7181-4939)
- Yong Xie (ORCID: https://orcid.org/0000-0001-9692-6593)
- Zhun Xu
- Xuelin Li (ORCID: https://orcid.org/0000-0001-8510-9387)
- Yi-ye Lu
- Hongyi Ye
Institutions
- University of South China (CN)
Publication Details
- Journal
- Bioactive Materials
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.bioactmat.2025.10.027
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00